About Incando Therapeutics
Incando Therapeutics is a company based in Belmont (United States) founded in 2019 by Charles Hu and Cheng Wei Pei. It operates as a B2B. Incando Therapeutics offers products and services including Deeplight Photodynamic Therapy and Implantable Photomedicine. Incando Therapeutics operates in a competitive market with competitors including PhotoPharmics, CranioVation, Adgero Biopharma, Lumeda and Illumi Medical, among others.
- Headquarter Belmont, United States
- Founders Charles Hu, Cheng Wei Pei
- SectorsHealthcare
- Email••••••••
- Website incandotherapeutics.com
- Social LinkedIn
Products & Services of Incando Therapeutics
Incando Therapeutics offers a comprehensive portfolio of products and services, including Deeplight Photodynamic Therapy and Implantable Photomedicine.
Wireless system for repeatable treatment of brain tumors.
Light-based device for improving cancer therapy safety.
People of Incando Therapeutics
2 people are tracked at Incando Therapeutics (2 in leadership).
| Name | Role | Group |
|---|---|---|
Charles Hu | Co-Founder | Leadership |
Cheng Wei Pei | Co-Founder | Leadership |
Complete people profiles for Incando Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Incando Therapeutics
Incando Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PhotoPharmics, CranioVation, Adgero Biopharma, Lumeda and Illumi Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| photopharmics.com | 2011 | American Fork, United States | $43.44M | – | Non-invasive phototherapy for Parkinson's disease is developed. | |
| craniovation.com | 2017 | Rochester, United States | $7.61M | – | Minimally invasive devices for brain tumor treatment are provided. | |
| adgerobiopharm.com | 2012 | Princeton, United States | $5.52M | – | Photodynamic therapy for cutaneous metastatic breast cancer is developed. | |
| lumedainc.com | 2020 | Rocky Hill, United States | $5.34M | 10 | Photodynamic therapy device for lung cancer treatment is developed. | |
| illumimedical.com | 2023 | Nagoya, Japan | $2.26M | – | Photodynamic therapy devices for cancer treatment are developed. | |
| spectracure.com | 2003 | Lund, Sweden | – | – | Developer of Interstitial photo dynamic therapy for solid tumours | |
| impactbiotech.com | 2022 | Ness Ziona, Israel | – | – | Developer of a drug delivery platform for the treatment of solid tumors | |
| photolitec.org | 2010 | Buffalo, United States | $5M | – | Supplies photosensitizing compounds for tumor imaging and photodynamic cancer therapy. | |
| illumacell.com | 2008 | Waterloo, Canada | – | – | Provider of medical light technology for photodynamic therapy cancer treatment |
Detailed competitors of Incando Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Incando Therapeutics
10 companies that operate in the same segment as Incando Therapeutics (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Incando Therapeutics
Incando Therapeutics was founded in 2019.
Incando Therapeutics is headquartered in Belmont, United States. It is registered at Belmont, California, United States.
Incando Therapeutics is a medical device company based in Hong Kong that focuses on creating light-based therapies for treating glioblastoma, a fatal brain cancer. They utilize patented wireless powering technology for photodynamic therapy, offering repeatable treatments with improved safety compared to traditional chemotherapy and radiation. The team collaborates with experts and institutions like John Hopkins Medicine to advance cancer care, targeting patients with recurring tumors.
Incando Therapeutics's top competitors include PhotoPharmics, ImPact Biotech and Adgero Biopharma.
Incando Therapeutics offers Deeplight Photodynamic Therapy and Implantable Photomedicine.